secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023788
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028
--------------------------------------------------------------------------------

- Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.
- Revenue $7.1M from FYARRO sales through March 25, 2025, date of divestiture to Kaken for $102.4M.
- Cash and equivalents $231.1M at March 31, 2025 (vs $47.2M Dec 31, 2024) after closing $100M PIPE.
- Expects cash of ~$185M after transaction payments, funding operations into 2028.
- Oncology ADC pipeline: three assets targeting PTK7, MUC16, SEZ6; first IND on track for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/0001628280-25-023788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/aadi-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer